Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hormone receptor positive, HER2-negative locally advanced carcinoma of breast, Hormone receptor positive, HER2-negative metastatic carcinoma of breast Age: Adult |
Dose: Oral – 600 mg Frequency: once daily Duration: 21 days followed by 7-days off to complete 28 days cycle Note: Taken preferably in the morning. Administered in combination with an aromatase inhibitor, or in combination with fulvestrant in postmenopausal women. Pre/perimenopausal women should be treated with luteinising hormone-releasing hormone agonist. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability. |
|
Indication: Hormone receptor positive, HER2-negative locally advanced carcinoma of breast, Hormone receptor positive, HER2-negative metastatic carcinoma of breast Age: Adult Condition: First dose reduction for management of adverse reactions |
Dose: Oral – 400 mg Frequency: once daily Duration: 21 days followed by 7-days off to complete 28 days cycle Note: Taken preferably in the morning. Discontinue if dose reduction below 200 mg once daily is required. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: NO_HEADER – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Mild-to-moderate renal impairment (Creatinine Clearance greater than or equal to 30 mL/min) |
Dose: Not specified Note: No dose adjustment necessary |
|
Condition: Severe renal impairment (Creatinine Clearance 15-30 mL/min) |
Dose: Not specified – 200 mg/day Frequency: once daily Note: Decrease starting dose to 200 mg/day; only studied healthy subjects and noncancer subjects with severe renal impairment |
Administration
- Take with or without food
- Take at same time each day
Side Effect
- Neutropenia (75%)
- Nausea (52%)
- Neutropenia, grade 3 (50%)
- Fatigue (37%)
- Diarrhea (35%)
- Leukopenia (33%)
- Alopecia (33%)
- Vomiting (29%)
- Constipation (25%)
- Headache (22%)
- Leukopenia, grade 3 (20%)
- Back pain (20%)
- Decreased appetite (19%)
- Anemia (18%)
- Abnormal LFTs (18%)
- Rash (17%)
- Pruritus (14%)
- Pyrexia (13%)
- Peripheral edema (12%)
- Stomatitis (12%)
- Insomnia (12%)
- Dyspnea (12%)
- Lymphopenia (11%)
- Urinary Tract Infection (UTI) (11%)
- Abdominal pain (11%)
- Neutropenia, grade 2 (10%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Amiodarone, disopyramide, chloroquine, bepridil, pimozide, moxifloxacin, tamoxifen
|
Increased risk of QT prolongation
|
|
Clarithromycin, indinavir, itraconazole, nefazodone
|
May increase plasma concentration and risk of toxicity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.